Skip to main content
. 2020 Feb 20;17(6):755–764. doi: 10.1080/15476286.2020.1730081

Figure 5.

Figure 5.

Protective effects of Bax siRNA in PMA-differentiated U937 cells. A1: RESV treated for 24 hr; A2: RESV treated for 48 hr; B1: No RESV treatment 24 hr; B2: No RESV treatment 48 hr; C1: Pretreated with 20 nM Bax siRNA and 1.0 µl DharmaFECT 3 for 24 hr then RESV treated for 24 hr; C2: Pretreated with 20 nM Bax siRNA and 1.0 µl DharmaFECT 3 for 24 hr then RESV treated for 48 hr. D: Number of dead cells in A1, B1, C1 and A2, B2, C2, information directly retrieved from Incucyte®. E: Percentage of dead cells compared to RESV treated; F: Representative Western blot analysis of PMA-differentiated U937 cells transfected with 20 nM Bax siRNA and 1.0 µl DharmaFECT 3 for 48 hr. G: Densitometry analysis of BAX and β-Actin protein bands from three independent Western blot experiments with results shown as mean ± SD (n = 3). * indicates p ≤ 0.05. ** indicates p ≤ 0.01.